Literature DB >> 10879739

T-cell-dependent fibrosis in the mdx dystrophic mouse.

J Morrison1, Q L Lu, C Pastoret, T Partridge, G Bou-Gharios.   

Abstract

In Duchenne muscular dystrophy patients, the pathological hallmark of the disease, namely, the chronic accumulation of sclerotic scar tissue in the interstitial space of skeletal muscle is attributed to manifestation of secondary pathological processes. Such anomalous generation of matrix protein is thought to be driven by the continuous degeneration and regeneration of muscle both in Duchenne Muscular Dystrophy and in the mdx mouse homolog. We examined mdx and the control strain C57bl/10 mice over a range of ages with respect to the amounts of collagen present in muscles and other organs, finding that the mdx have significantly higher collagen content at later time points in their kidney and lung as well as their muscles. Surprisingly, when we bred the mdx mice on the nu/nu background, the time course of fibrogenesis was modified depending on the tissue and the collagen content was significantly different in age-matched mice. Transplantation of normal thymic tissue into the mdx-nu/nu mice replenished their T-cells and concomitantly altered the collagen content in their tissues to levels comparable with those in immunocompetent mdx mice. This suggests that T-cells play a role in the onset of the fibrotic events that undermines the ability of dystrophic muscle to regenerate.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10879739     DOI: 10.1038/labinvest.3780092

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  52 in total

1.  Lack of the serum- and glucocorticoid-inducible kinase SGK1 improves muscle force characteristics and attenuates fibrosis in dystrophic mdx mouse muscle.

Authors:  Martin Steinberger; Michael Föller; Silke Vogelgesang; Mirjam Krautwald; Martin Landsberger; Claudia K Winkler; Joachim Kasch; Ernst-Martin Füchtbauer; Dietmar Kuhl; Jakob Voelkl; Florian Lang; Heinrich Brinkmeier
Journal:  Pflugers Arch       Date:  2014-11-14       Impact factor: 3.657

Review 2.  Duchenne's muscular dystrophy: animal models used to investigate pathogenesis and develop therapeutic strategies.

Authors:  C A Collins; J E Morgan
Journal:  Int J Exp Pathol       Date:  2003-08       Impact factor: 1.925

3.  The effects of glucocorticoid therapy on the inflammatory and dendritic cells in muscular dystrophies.

Authors:  Mahmoud R Hussein; Sherifa A Hamed; Mohammed G Mostafa; Eman E Abu-Dief; Nageh Fouly Kamel; Mahmoud R Kandil
Journal:  Int J Exp Pathol       Date:  2006-12       Impact factor: 1.925

4.  Chronic infection stunts macrophage heterogeneity and disrupts immune-mediated myogenesis.

Authors:  Richard M Jin; Jordan Warunek; Elizabeth A Wohlfert
Journal:  JCI Insight       Date:  2018-09-20

Review 5.  What do mouse models of muscular dystrophy tell us about the DAPC and its components?

Authors:  Charlotte Whitmore; Jennifer Morgan
Journal:  Int J Exp Pathol       Date:  2014-09-30       Impact factor: 1.925

6.  Extraocular muscle satellite cells are high performance myo-engines retaining efficient regenerative capacity in dystrophin deficiency.

Authors:  Pascal Stuelsatz; Andrew Shearer; Yunfei Li; Lindsey A Muir; Nicholas Ieronimakis; Qingwu W Shen; Irina Kirillova; Zipora Yablonka-Reuveni
Journal:  Dev Biol       Date:  2014-09-16       Impact factor: 3.582

7.  Association Study of Exon Variants in the NF-κB and TGFβ Pathways Identifies CD40 as a Modifier of Duchenne Muscular Dystrophy.

Authors:  Luca Bello; Kevin M Flanigan; Robert B Weiss; Pietro Spitali; Annemieke Aartsma-Rus; Francesco Muntoni; Irina Zaharieva; Alessandra Ferlini; Eugenio Mercuri; Sylvie Tuffery-Giraud; Mireille Claustres; Volker Straub; Hanns Lochmüller; Andrea Barp; Sara Vianello; Elena Pegoraro; Jaya Punetha; Heather Gordish-Dressman; Mamta Giri; Craig M McDonald; Eric P Hoffman
Journal:  Am J Hum Genet       Date:  2016-10-13       Impact factor: 11.025

8.  Valproic acid activates the PI3K/Akt/mTOR pathway in muscle and ameliorates pathology in a mouse model of Duchenne muscular dystrophy.

Authors:  Praveen B Gurpur; Jianming Liu; Dean J Burkin; Stephen J Kaufman
Journal:  Am J Pathol       Date:  2009-01-29       Impact factor: 4.307

9.  Amelioration of laminin-alpha2-deficient congenital muscular dystrophy by somatic gene transfer of miniagrin.

Authors:  Chunping Qiao; Jianbin Li; Tong Zhu; Romesh Draviam; Simon Watkins; Xiaojing Ye; Chunlian Chen; Juan Li; Xiao Xiao
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-15       Impact factor: 11.205

Review 10.  Immune-mediated mechanisms potentially regulate the disease time-course of duchenne muscular dystrophy and provide targets for therapeutic intervention.

Authors:  Nicholas P Evans; Sarah A Misyak; John L Robertson; Josep Bassaganya-Riera; Robert W Grange
Journal:  PM R       Date:  2009-08       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.